Key Takeaways from #ESMO20 on Breast Cancer

Key Takeaways from ESMO: CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer

Lee Schwartzberg

1. How are CDK 4/6 inhibitors currently used in hormone receptor-positive breast cancer?
2. What are some of the key questions that remain about this class of drugs that were addressed at this year's ESMO?
3. What other trials on CDK4/6 inhibitors are practice-informing?
4. What kind of data do we have comparing the different CDK 4/6 inhibitors?

Key Takeaways from ESMO: Adjuvant HR+ Breast Cancer

Sara Tolaney

1. What are some of the most important studies pertaining to the adjuvant treatment of breast cancer being presented at this year's ESMO?
2. Was there any subset analysis in the palbociclib study for either the discontinuation patients or the high-risk patients that might give you some signal to say that what you saw in the metastatic setting remains true in the adjuvant setting?